Identity floor
Borrower identity here is a normalised-name match — the majority join in the private-credit books, with roughly 10% measured error in each direction (two companies fused into one, or one company split across spellings). Figures built on it — crowding, overlap, the manager complex — are floors, not exact counts. How this is measured →
Fair value and share of that fund's resolved holdings book, each at the fund's own most recent reported period — the as-of column, because the holders of one company do not file on one date. The bar under each fair value is that fund's share of the $63M combined total across every holder — a different denominator from the share-of-book column — so one dominant lender vs an even syndicate is visible without reading the dollar figures.
| Fund | As of | Fair value | Share of book |
|---|---|---|---|
| FS KKR Capital Corp.⚠ unreconciledKKR · matched: name | 2026-03-31 | $42M | 0.2% |
| KKR FS Income Trust⚠ unreconciledKKR · matched: name | 2026-03-31 | $21M | 0.6% |
The range across reported debt positions in the same borrower — fair value over amortized cost as filed — for 2 funds holding it in Q1'26.
2 funds · 4 positions · Q1'26
Instrument stated on 4 of 4 positions (100%).
Positions counted here filed a principal balance — the debt proxy used to find comparable marks, measured 82% precise as actual debt where an instrument label exists; the rest are equity or warrants filed with a principal amount.
| Fund | Instrument | Fair value | Mark | Band |
|---|---|---|---|---|
| FS KKR Capital Corp.⚠ unreconciledmatched: name · 2026-03-31 | Pharmaceuticals, Biotechnology & Life Sciences Other debt | $21M | 101.0% | Unstressed |
| FS KKR Capital Corp.⚠ unreconciledmatched: name · 2026-03-31 | Pharmaceuticals, Biotechnology & Life Sciences Other debt | $21M | 101.0% | Unstressed |
| KKR FS Income Trust⚠ unreconciledmatched: name · 2026-03-31 | Pharmaceuticals, Biotechnology & Life Sciences Other debt | $10M | 101.0% | Unstressed |
| KKR FS Income Trust⚠ unreconciledmatched: name · 2026-03-31 | Pharmaceuticals, Biotechnology & Life Sciences Other debt | $11M | 102.2% | Unstressed |
Source: AltsVault · SEC filings · as of 2026-01-01
AltsVault · SEC EDGAR public data · informational only, not investment advice. Reconciliation is marked per fund on each position row.